IITRI NEWS

NEWS

We are ready to answer your questions and provide guidance.

News

Zika Virus (ZIKV) Mouse Pregnancy Model Now Available

A mouse pregnancy model is now available from IITRI to evaluate the ability of vaccines or antivirals for protection against Zika virus (ZIKV) maternal-fetal viral transmission and resulting fetal defects such as microcephaly. Details of this mouse model and its use...

IITRI Announces New Flow Cytometry Services

IITRI is pleased to announce the addition of immunophenotyping services using flow cytometry to our ex vivo assay offerings. In flow cytometry, multiple properties can be analyzed simultaneously at the single cell level by generating a stream of cells in single-file...

IITRI Announces Expansion of Immunology Capabilities

IITRI is pleased to announce the expansion of our infectious disease immunology capabilities with the recent hiring of Justin Richner, PhD, to the position of Research Biologist, Viral Immunology. Dr. Richner’s research focus includes viral pathogenesis and host...

IITRI Chosen As Member of Nonclinical Studies Network

IITRI Chosen As Member of Nonclinical Studies Network

IITRI was one of 7 organizations chosen as a member of a Nonclinical Studies Network created by BARDA to aid in the successful development of medical countermeasures for biological threats. Nonclinical studies supporting treatments for biological threats is especially...

IITRI at IMED Meeting on Zika Mouse and Macaques Models

IITRI at IMED Meeting on Zika Mouse and Macaques Models

IITRI will be presenting at the upcoming International Meeting on Emerging Diseases and Surveillance (IMED) November 4-7, 2016 in Vienna, Austria, on Zika Mouse and Macque Models developed by our Molecular and Microbiology team. For more details, please contact us....

IITRI Awarded Over $4.7M BARDA Contracts

IITRI Awarded Over $4.7M BARDA Contracts

IITRI announces the recent award of three major new programs by the Biomedical Advanced Research and Development Authority (BARDA) valued at more than $4.7 M. The programs are for the development and/or evaluation of cutting edge technologies and agents to control...

NCI Awards IITRI $29.8 Million for Two New Preclinical Programs

The National Cancer Institute’s Division of Cancer Treatment and Diagnosis (DCTD) has awarded IITRI $29.8 million for two major 5-year new programs. The DCTD supports many programs that facilitate the development of cancer therapeutics from the bench to the patient,...

ASCO 2016 Poster with Singh Biotechnology, LLC

ASCO 2016 Poster Presented IITRI co-authored a poster presented at the recent American Society of Clinical Oncology (ASCO) meeting in Chicago, IL. The poster, A novel single domain antibody (sdAb) SBT-100 to target intracellular STAT3 to affect growth and regression...

IITRI Announces Membership in NCBD Consortium

IITRI Announces Membership in NCBD Consortium

IITRI Joins National Chemical & Biological Defense Consortium IITRI is pleased to announce our acceptance as a member into the National Chemical & Biological Defense Consortium (NCBDC). The mission of the Consortium will be to provide the US Department of...

IITRI Announces Zika Mouse Model Available

IITRI is on the leading edge for testing new Zika vaccines and antivirals CHICAGO, May 9, 2016 /PRNewswire-USNewswire/ -- IIT Research Institute (IITRI) scientists have developed a novel mouse model for Zika infections using the current viral strain responsible for...